These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26835516)

  • 1. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.
    Ananworanich J; Chomont N; Fletcher JL; Pinyakorn S; Schuetz A; Sereti I; Rerknimitr R; Dewar R; Kroon E; Vandergeeten C; Trichavaroj R; Chomchey N; Chalermchai T; Michael NL; Kim JH; Phanuphak P; Phanuphak N
    J Virus Erad; 2015; 1(2):116-122. PubMed ID: 26835516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.
    Ananworanich J; Schuetz A; Vandergeeten C; Sereti I; de Souza M; Rerknimitr R; Dewar R; Marovich M; van Griensven F; Sekaly R; Pinyakorn S; Phanuphak N; Trichavaroj R; Rutvisuttinunt W; Chomchey N; Paris R; Peel S; Valcour V; Maldarelli F; Chomont N; Michael N; Phanuphak P; Kim JH;
    PLoS One; 2012; 7(3):e33948. PubMed ID: 22479485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.
    Lafeuillade A; Assi A; Poggi C; Bresson-Cuquemelle C; Jullian E; Tamalet C
    AIDS Res Ther; 2014; 11(1):33. PubMed ID: 25320633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection.
    Ananworanich J; Sacdalan CP; Pinyakorn S; Chomont N; de Souza M; Luekasemsuk T; Schuetz A; Krebs SJ; Dewar R; Jagodzinski L; Ubolyam S; Trichavaroj R; Tovanabutra S; Spudich S; Valcour V; Sereti I; Michael N; Robb M; Phanuphak P; Kim JH; Phanuphak N
    J Virus Erad; 2016; 2(1):43-48. PubMed ID: 26889497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of immunoglobulin in acute HIV infection on the HIV reservoir: a randomized controlled trial.
    Tiraboschi J; Ray S; Patel K; Teague A; Pace M; Phalora P; Robinson N; Hopkins E; Meyerowitz J; Wang Y; Cason J; Kaye S; Sanderson J; Klenerman P; Fidler S; Frater J; Fox J
    HIV Med; 2017 Nov; 18(10):777-781. PubMed ID: 28719012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
    Massanella M; Esteve A; Buzón MJ; Llibre JM; Puertas MC; Gatell JM; Domingo P; Stevenson M; Clotet B; Martinez-Picado J; Blanco J;
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):152-60. PubMed ID: 23392458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.
    Ruggiero A; De Spiegelaere W; Cozzi-Lepri A; Kiselinova M; Pollakis G; Beloukas A; Vandekerckhove L; Strain M; Richman D; Phillips A; Geretti AM;
    EBioMedicine; 2015 Sep; 2(9):1153-9. PubMed ID: 26498496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
    Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens.
    Phanuphak N; Teeratakulpisarn N; van Griensven F; Chomchey N; Pinyakorn S; Fletcher JL; Trichavaroj R; Pattanachaiwit S; Michael N; Phanuphak P; Kim JH; Ananworanich J;
    J Int AIDS Soc; 2015; 18(1):19470. PubMed ID: 25956171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
    Achenbach CJ; Assoumou L; Deeks SG; Wilkin TJ; Berzins B; Casazza JP; Lambert-Niclot S; Koup RA; Costagliola D; Calvez V; Katlama C; Autran B; Murphy RL;
    Lancet HIV; 2015 Mar; 2(3):e82-91. PubMed ID: 26424549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation.
    Crowell TA; Fletcher JL; Sereti I; Pinyakorn S; Dewar R; Krebs SJ; Chomchey N; Rerknimitr R; Schuetz A; Michael NL; Phanuphak N; Chomont N; Ananworanich J;
    J Int AIDS Soc; 2016; 19(1):21163. PubMed ID: 27637172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
    Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
    AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
    Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
    J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
    Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
    J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
    Lam YM; McBride KL; Amin J; Cordery DV; Kelleher AD; Cooper DA; Koelsch KK
    PLoS One; 2012; 7(3):e31990. PubMed ID: 22396745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.